Imugene (IMU.AX) Stock Price
Imugene Price
Revenue has compounded at 55.4% per year over the past 18 years to 4.40 M AUD. Imugene's net margin stands at -1,569.8%, down from -255.2% several years earlier.
Imugene stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Imugene business model & stock analysis
Frequently asked questions about Imugene
Imugene Ltd is a biotechnology company specializing in the development and commercialization of innovative immunotherapies for the treatment of various cancers. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to create targeted and personalized immunotherapies that activate the body's own immune system to fight cancer. Imugene aims to improve patient outcomes and address the unmet medical needs in oncology by advancing their immunotherapy pipeline. With a focus on developing novel treatments and strategic partnerships, Imugene is dedicated to making a significant impact in the field of cancer immunotherapies.
Imugene Ltd is primarily active in the biotechnology industry.
The main competitors of Imugene Ltd in the market include major biopharmaceutical companies such as Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, and Pfizer Inc. These companies also specialize in developing innovative treatments and therapies for various diseases and disorders.
Imugene Ltd is a biopharmaceutical company dedicated to developing innovative immunotherapies to treat cancer. Founded in 1983, Imugene has a rich history in the field of oncology research and drug development. The company focuses on creating targeted immunotherapies that harness the power of the immune system to fight cancer cells. Imugene is committed to addressing unmet medical needs and improving patient outcomes. With a strong team of experienced scientists and a robust pipeline of promising drug candidates, Imugene aims to revolutionize cancer treatment and provide hope to patients worldwide. Imugene Ltd continues to strive towards its mission of developing much-needed advancements in the oncology field.
Imugene Ltd has achieved several significant milestones. The company successfully completed a Phase 1b study for its HER-Vaxx cancer immunotherapy in gastric cancer patients. Imugene also received approval from the US FDA to initiate its Phase 2 study for HER-Vaxx in gastric cancer. Additionally, Imugene has entered collaborations with renowned academic institutions, including City of Hope, to conduct preclinical and clinical trials for various cancer treatments. The company has made considerable progress in advancing its innovative immunotherapy pipeline, which shows great potential in the field of oncology. Imugene Ltd continues to strive for excellence and breakthroughs in cancer treatments.
Imugene Ltd is primarily present in Australia, United States, and Europe.
Imugene Ltd represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize cancer treatment through its cutting-edge immunotherapy technologies. Imugene prioritizes scientific expertise and fosters strategic partnerships to advance its pipeline of novel and targeted therapies. The company's commitment to improving treatment outcomes for patients is evidenced by its emphasis on clinical development, rigorous research, and commercialization of innovative products. Imugene's inclusive approach promotes open communication and collaboration among researchers, clinicians, and industry experts, reinforcing its dedication to making a significant impact in the fight against cancer.
5 analysts currently rate the Imugene stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Imugene share trades at 0.02 EUR (0.04 AUD).
The Imugene share (IMU.AX) is listed on 2 stock exchanges, including: ASX (IMU.AX).
Imugene Ltd is an Australian biopharmaceutical company that focuses on researching, developing, and marketing innovative therapeutic solutions for the treatment of cancer and infectious diseases. The company uses a unique technology platform to responsibly develop immuno-oncology products. Imugene is headquartered in Sydney, Australia, and has additional offices in the USA and Europe. The four main business areas of Imugene are: 1) Immuno-Oncology Products, 2) Immunomodulating Solutions in Cancer, 3) Infectious Diseases, and 4) Partner Programs. Imugene aims to expand its portfolio of immunotherapeutics through new product development and collaborations. It strives to revolutionize the treatment of cancer and infectious diseases with its unique technology platform and comprehensive portfolio of immunotherapeutics. Imugene is well-positioned to become a leading player in the biopharmaceutical industry with its presence in Australia, the USA, and Europe.
The revenue cannot currently be calculated for Imugene.
The profit of Imugene is -105.34 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Imugene is currently -0.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Imugene stock.
The P/S cannot be calculated for Imugene currently.
The Eulerpool Quality Score for Imugene is 4/10.
The ISIN of Imugene is AU000000IMU9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Imugene is 891460. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Imugene is IMU.AX. The ticker symbol is used to trade Imugene shares on the stock exchange.
Imugene stock
Imugene Peer Group
Imugene Ticker
Imugene FIGI
All fundamentals and in-depth analysis of Imugene
Our stock analysis for Imugene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.